Altimmune Welcomes New Chief Financial Officer, Greg Weaver
Altimmune, Inc. (NASDAQ: ALT), a pioneering clinical-stage biopharmaceutical entity, has recently made a significant leadership change by appointing Greg Weaver as their Chief Financial Officer (CFO). This appointment promises to bring a wealth of experience and strategic direction to the company's financial management, particularly at a time when it is poised for growth and innovation.
The Importance of Leadership in Times of Change
Greg Weaver's onboarding is seen as a critical step for Altimmune as they navigate pivotal developments in their lead program, pemvidutide. This innovative venture targets metabolic disorders, with the potential to reshape treatment paradigms in obesity and liver diseases. The leadership of Weaver, paired with Altimmune’s distinguished team, is expected to enhance the company’s trajectory during this transformative period.
Expertise That Matters
With over 25 years of financial expertise in both publicly listed and private life sciences firms, Mr. Weaver’s experience is a valuable asset. Prior to Altimmune, he served as CFO at Cognito Therapeutics, where he contributed to strategies aimed at combating neurodegenerative diseases. He also led financial initiatives during his tenure at atai Life Sciences (NASDAQ: ATAI), overseeing a substantial Initial Public Offering in 2021.
Building on a Legacy of Leadership
Throughout his career, Mr. Weaver has not only led corporate financial departments but has also been involved in various aspects of financial strategy, ranging from M&A efforts to significant fundraising campaigns. His past roles included CFO titles at notable biotech companies, with a proven track record of success that speaks to his capabilities in scaling organizations financially.
Strategic Vision for Pemvidutide
In his new role, Weaver expressed excitement about the unique opportunity presented by pemvidutide—a GLP-1/glucagon dual receptor agonist. He noted the substantial promise of this candidate in addressing metabolic disorders due to its targeted mechanism and effective lipid-lowering properties. The early data regarding its performance in obesity and liver diseases are optimistic, and as Weaver puts it, Altimmune is on the brink of important milestones in this sector.
Engagement with Industry and Community
Weaver's connection to the industry runs deep, as he is also involved with various organizations, holding positions such as Director and Chair of the Audit Committee at BioIntelliSense, a leading patient monitoring technology company. Furthermore, he has contributed to clinical-stage developments at Centenara Labs, focusing on the science of aging, demonstrating a commitment to advancing healthcare beyond his immediate corporate responsibilities.
A Dedication to Service
Adding to his impressive profile, Weaver is a veteran of the United States Air Force. He harnesses discipline and leadership skills gained from his service and applies them to his professional life, bridging efforts between financial stewardship and innovative healthcare solutions. His educational background includes a bachelor’s degree in Accounting and Finance from Trinity University and an MBA from Boston College, showcasing a robust foundation in both financial management and strategic business leadership.
About Altimmune, Inc.
Altimmune is a cutting-edge clinical-stage biopharmaceutical firm dedicated to the development of next-generation peptide-based therapeutics. With a focus on innovative solutions like pemvidutide aimed at treating metabolic diseases, Altimmune is committed to enhancing patient outcomes and driving scientific advancements in the healthcare landscape.
Frequently Asked Questions
Who is Greg Weaver?
Greg Weaver is the newly appointed Chief Financial Officer of Altimmune, Inc., bringing over 25 years of experience in the life sciences industry.
What is pemvidutide?
Pemvidutide is a GLP-1/glucagon dual receptor agonist in development by Altimmune for addressing obesity and liver diseases.
What experience does Greg Weaver have?
Weaver has notably served as CFO of Cognito Therapeutics and atai Life Sciences, leading significant financial developments and IPOs throughout his career.
How does Altimmune plan to grow under new leadership?
With Weaver’s strategic financial leadership, Altimmune aims to enhance its programs, notably pemvidutide, and solidify its position in the biopharmaceutical market.
Where can I find more information about Altimmune?
For more information, you can visit the company’s website at www.altimmune.com.
